Abstract Types

Clinical Review Abstract

Late-Breaking Abstract

Trials in Progress Abstract

Abstracts selected for publication but not presentation at the Annual Meeting

Abstracts granted an exception in accordance with ASCO's Conflict of Interest Policy

Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance.

Pancreatic Cancer

Gastrointestinal (Noncolorectal) Cancer

2013 ASCO Annual Meeting

Abstract No:

J Clin Oncol 31, 2013 (suppl; abstr 4017)

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2013 Annual Meeting but not presented at the Meeting, can be found online only.

Author(s): Kenneth H. Yu, Vineet Sangar, Mark Ricigliano, Manuel Hidalgo, Ghassan K. Abou-Alfa, Maeve Aine Lowery, Leonard Saltz, Joseph F. Crotty, Kristen Gary, Jing Yin, Eun Yong Choi, Eileen Mary O'Reilly; Memorial Sloan-Kettering Cancer Center, New York, NY; Institute for Systems Biology, Seattle, WA; CellPath Therapeuthics, Inc, Baltimore, MD; Spanish National Cancer Research Center (CNIO), Madrid, Spain; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD

Abstract Disclosures


Background: Pancreatic adenocarcinoma (PDAC) is uniformly lethal and is the 4th leading cause of cancer mortality. Despite this, modern cytotoxics (C) can induce tumor responses and extend life. Xenograft models have shown that pharmacogenomic (PGx) modeling of C can predict efficacy. Chemo-sensitivity and gene expression profiling of circulating tumor and invasive cells (CTICs) isolated from peripheral blood may predict tumor response, progression and resistance. Methods: A prospective MSKCC study has completed planned accrual of 50 patients. 10 mL of peripheral blood is collected from patients with unresectable PDAC prior to C and at disease progression. Clinical data is prospectively collected. CTICs are isolated (Vita-Cap, Vitatex Inc.), total RNA is extracted and gene-expression analysis is performed. PGx models for twelve chemotherapy drug combinations used in PDAC were created from the GI50 data obtained from the NCI-60 cell lines (CellPath Therapeutics, Inc., Baltimore, MD). Expression data were normalized through GCRMA then probed to identify expression differences between patients with short v long TTP and within patients at baseline v at time of progression. The analysis was performed at the pathway and individual gene level. Results: CTICs were isolated, and gene expression and chemo-sensitivity patterns were obtained in all 50 patients prior to initiating C and in 20 patients at 1st line disease progression. Preliminary analysis demonstrates clinical benefit for patients treated with C predicted to be effective versus ineffective (TTP 7.3 mo v 3.7 mo, p=0.017, HR 0.30). Changes in chemo-sensitivity patterns were evident at disease progression, reflecting treatment resistance. Pathway analysis revealed that E2F1 and NFκB pathways are associated with prognosis, PLC and RB1 pathways become disrupted with disease progression. Conclusions: Isolation and gene expression profiling of CTICs can be performed reliably in unresectable PDAC. Preliminary analysis suggests that C profiling can predict response. Repeat PGx profiling identifies key pathways associated with treatment resistance. Clinical trial information: NCT01474564.


  Other Abstracts in this Sub-Category:


1. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.

Meeting: 2013 ASCO Annual Meeting Abstract No: LBA4003 First Author: P. Hammel
Category: Gastrointestinal (Noncolorectal) Cancer - Pancreatic Cancer


2. A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.

Meeting: 2013 ASCO Annual Meeting Abstract No: LBA4004 First Author: G. W. Middleton
Category: Gastrointestinal (Noncolorectal) Cancer - Pancreatic Cancer


3. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.

Meeting: 2013 ASCO Annual Meeting Abstract No: 4005^ First Author: D. D. Von Hoff
Category: Gastrointestinal (Noncolorectal) Cancer - Pancreatic Cancer